Compare DNUT & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DNUT | ZLAB |
|---|---|---|
| Founded | 1937 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 577.8M | 2.6B |
| IPO Year | 2021 | 2017 |
| Metric | DNUT | ZLAB |
|---|---|---|
| Price | $3.25 | $25.58 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $4.15 | ★ $49.60 |
| AVG Volume (30 Days) | ★ 3.0M | 1.0M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.46 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,522,616,000.00 | $460,156,000.00 |
| Revenue This Year | $0.55 | $9.75 |
| Revenue Next Year | $3.59 | $26.03 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 15.33 |
| 52 Week Low | $2.88 | $15.96 |
| 52 Week High | $5.11 | $35.45 |
| Indicator | DNUT | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 48.67 | 74.29 |
| Support Level | $3.06 | $16.98 |
| Resistance Level | $3.43 | $26.66 |
| Average True Range (ATR) | 0.17 | 1.18 |
| MACD | 0.02 | 0.58 |
| Stochastic Oscillator | 41.18 | 87.53 |
Krispy Kreme Inc is a sweet-treat brand company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in-mouth experience. It operates through its network of fresh Doughnut Shops, partnerships with retailers, and a growing e-commerce and delivery business. The company conducts its business through the following three reported segments: U.S., which includes all operations in the United States; International, which includes operations in the U.K., Ireland, Australia, New Zealand, Canada, Japan, and Mexico; and Market Development, which includes franchise operations world-wide. It derives maximum revenue from the U.S. segment.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.